Agenus shared a post on LinkedIn:
“New Phase 2 data for BOT+BAL in advanced checkpoint-refractory melanoma will be presented at ASCO26.
In a heavily pretreated population whose disease had resisted prior checkpoint therapy and who often had poor-risk features, BOT+BAL showed durable responses and encouraging survival.
In the overall BOT+BAL-treated population:
- Median overall survival was 16.6 months.
- 42% of patients were alive at two years.
These data add to the growing body of evidence supporting BOT+BAL’s potential to generate durable immune benefit across difficult-to-treat and historically immunotherapy-resistant tumors.
Other articles about Melanoma on OncoDaily.